

## Thomson Scientific

Middlesex House  
34-42 Cleveland Street  
London  
W1T 4JE  
UK  
Tel +44 (0)20 7070 6565  
Fax +44 (0)20 7070 6570  
Email: TS.Custserv.EMEA@thomson.com

**Managing Editor** Barbara Chan  
Email: barbara.chan@thomson.com

## Editorial Board

Dale Ando (USA)  
Jean-Paul Behr (France)  
C Frank Bennett (USA)  
Joseph Bertino (USA)  
Thierry Bogaert (Belgium)  
Ernst Böhnlein (USA)  
Klaus Cichutek (Germany)  
Howard Cooke (UK)  
Michael Courtney (France)  
Charles C Coutelle (UK)  
Pieter Cullis (Canada)  
David T Curiel (USA)  
Olivier Danos (France)  
Maria de Lima (Portugal)  
Barbara Demeneix (France)  
David Ennist (USA)  
Jonathan Fletcher (USA)  
Wolf Fridman (France)  
Bernd Gansbacher (Germany)  
Michael Gilman (USA)  
Richard Gregory (USA)  
Dieter C Gruenert (USA)  
Evan Hersh (USA)  
Ian Humphery-Smith (Netherlands)  
George Karpati (Canada)  
David Klatzmann (France)  
Nicholas R Lemoine (UK)  
Margaret A Liu (USA)  
Kim Lyerly (USA)  
François Meyer (France)  
Sigrid Nikol (Germany)  
Jon A Norman (USA)  
Elizabeth Rollinson (UK)  
Michael Salgaller (USA)  
Kevin Scanlon (USA)  
Karol Sikora (UK)  
George Stamatoyannopoulos (USA)  
Sean Sullivan (USA)  
Dinko Valerio (Netherlands)  
Richard Vile (USA)  
Jerry Vovis (USA)  
Chester Whitley (USA)

## Contents

The subject of molecular therapeutics is divided into six major sections, each of which is reviewed once a year. Each issue focuses on one of the major sections, and features highlights of the other sections.

### February 2007

#### **Molecular, viral and cell-based vaccines for disease prevention and therapy**

Edited by Michael A Morse & Michael Whelan

### April 2007

#### **Oligonucleotide, antibody and peptide therapeutics – from design to the clinic**

Edited by John Goodchild & Patrick L Iversen

### June 2007

#### **Genomics, proteomics and pharmacogenetics – experimental approaches**

Edited by Lex Cowser, Lukas A Huber, Howard McLeod & Jennifer E Van Eyk

### August 2007

#### **Gene transfer and cell-based therapies**

Edited by Walter Günzburg, Terry Hermiston & Leonard W Seymour

### October 2007

#### **Clinical applications of gene therapy**

Edited by Pedro Lowenstein, Joseph Rosenecker & John Tisdale

### December 2007

#### **Genomics, proteomics and pharmacogenetics – therapeutic approaches**

Edited by Lex M Cowser, Lukas A Huber, Howard L McLeod & Jennifer E Van Eyk

# Current Opinion in Molecular Therapeutics

**Current Opinion in Molecular Therapeutics** ISSN 1464-8431 is published bimonthly by:

**Thomson Scientific**  
**Middlesex House**  
**34-42 Cleveland Street**  
**London**  
**W1T 4JE**  
**UK**

Tel: +44-(0)20 7070 6565  
Fax: +44(0)20 7070 6570  
Email: TS.Custserv.EMEA@thomson.com

**Editorial Director** Bernadette Swords  
**Managing Editor (Journal)** Barbara Chan  
**Managing Editor (Evaluations)** Sue Gotham  
**In-house Editors (Evaluations)** Peter Aylett, Ulrike Jahnke, Rodolfo Medina, Tom Phillips, Paul Whittingham  
**Assistant Editors** Timur Mehmet, Amanda Singleton, Peter Stanislas  
**Production Manager** Alexandra Acheson  
**Production Editor** Debbie Wallbank  
**Cover design** © 2007 Andrew SR Featherstone  
- Research Graphix

## Copyright © 2007 Thomson Scientific

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any electronic or other form without prior permission of the copyright owner.

Article reprints are available through Thomson Scientific's reprint service. For information contact: ts.ids@thomson.com

Whilst every effort is made by the publisher and editorial board to see that no inaccurate or misleading data, opinion or statement appear in this journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the publishers, the editorial board and section editors and their respective employees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement.

## Current Opinion in Molecular Therapeutics

is indexed by *Index Medicus*, MEDLINE, EMBASE/Excerpta Medica, Chemical Abstracts, Derwent Drug File, Science Citation Index-Expanded®, Index to Scientific Reviews®, Research Alert®, CAB ABSTRACTS, GLOBAL HEALTH, Biotechnology Citation Index® and Journal Citation Reports®.

Printed in the UK by Cats.

## Aims and organization

The *Current Opinion* journals were developed out of the recognition that specialists have increasing difficulty keeping up to date with the expanding volume of information published in their subject. In *Current Opinion in Molecular Therapeutics*, we aim to help the reader by providing in a systematic manner:

- the views of experts on current advances in molecular therapeutics in a clear and readable form;
- selection of the most interesting papers from the great wealth of original publications, annotated by experts.

## Division of the subject into sections

The subject of molecular therapeutics is divided into six major sections, each of which is reviewed once a year.

## Selection of topics to be reviewed

Section Editors, who are major authorities in the field, are appointed by the Editors of the journal. They divide their section into a number of topics, ensuring that the field is comprehensively covered and that all issues of current importance are emphasized. Section Editors commission reviews from authorities on each topic that they have selected.

## Reviews

Authors write short reviews in which they present recent developments in their subject, emphasizing the aspects that, in their opinion, are most important. In addition, they provide short annotations to the papers that they consider to be the most interesting from all those published in their topic over the previous year. Papers chosen by a reviewer as being 'of special interest' or 'of outstanding interest' are clearly identified in the reference list at the end of each review.

## Editorial overview

Section Editors write a short overview at the beginning of the section to introduce the reviews and to draw the readers attention to any particularly interesting developments.

## Web alert

A selection of World Wide Web sites relevant to the contents of *Current Opinion in Molecular Therapeutics* are included in each issue.

## Paper and Patent alerts

Commentary on a selection of recently published papers and patents, identified as being of particular interest, is provided.

## Annual indexes

In the last issue of each volume, cumulative indexes of contents, subjects and authors are provided.

## Subscription information

Subscription rates include airspeed delivery

	North America	Japan	Rest of World
Corporate	\$ 3896	¥ 624,100	£ 2458
Additional copy	\$ 2143	¥ 343,255	£ 1352
Academic rate	\$ 2143	¥ 343,255	£ 1352

## Orders

*All orders (except for Japan) should be placed with*

Thomson Scientific  
Sales Order Processing Department  
1st Floor, Holbrook House  
14 Great Queen Street  
London  
WC2B 5DF  
UK

Tel +44 (0) 20 7344 2800  
Fax +44 (0) 20 7344 2972

## Orders for Japan

Technomics Inc  
Nihonbashi TM Bldg  
1-8-11 Nihonbashi  
Horidome-cho  
Chuo-ku  
Tokyo 103-0012  
Japan

Tel +81 3 3666 2952  
Fax +81 3 3666 2730

## Subscription queries

Thomson Scientific  
Sales Order Processing Department  
1st Floor, Holbrook House  
14 Great Queen Street  
London  
WC2B 5DF  
UK

Tel +44 (0) 20 7344 2800  
Fax +44 (0) 20 7344 2972

In case of particular difficulty please contact  
TS.custserv.EMEA@thomson.com

## Paper alert

---

1 **Marc Greener & Robert E Hurst**

## Patent alert

---

5 **Thomson Scientific Current Awareness Analysts**

## Web alert

---

8 **Alick C Stephens**

## Molecular, viral and cell-based vaccines for disease prevention and therapy

Edited by Michael A Morse & Michael Whelan

---

## Editorial overview

---

10 **Michael A Morse & Michael Whelan**  
Learning from each other: Applying observations from anti-tumor, anti-pathogen and anti-toxin immunotherapy

## Reviews

---

- 12 **Judith E Epstein, Birgitte Giersing, Gregory Mullen, Vasee Moorthy & Thomas L Richie**  
Malaria vaccines: Are we getting closer?
- 25 **Colleen Olive**  
Progress in M-protein-based subunit vaccines to prevent rheumatic fever and rheumatic heart disease
- 35 **Angela Liakatos & Horst Kunz**  
Synthetic glycopeptides for the development of cancer vaccines
- 45 **Claudia A Daubenberg**  
TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines
- 53 **Yuzuru Ikehara & Naoya Kojima**  
Development of a novel oligomannose-coated liposome-based anticancer drug-delivery system for intraperitoneal cancer
- 62 **Yalonda Hutchings, Takuya Osada, Christopher Y Woo, Timothy M Clay, H Kim Lyerly & Michael A Morse**  
Immunotherapeutic targeting of Wilms' tumor protein
- 70 **Ryan Wilcox & Svetomir N Markovic**  
Tumor immunotherapy in melanoma: On the dawn of a new era?
- 79 **Beka Solomon**  
Intravenous immunoglobulin and Alzheimer's disease immunotherapy

## Drug evaluations

---

- 86 **Lloyd Kelland**  
ADH-1, an N-cadherin antagonist targeting cancer vascularization
- 92 **Scott K Kuwada**  
Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody

**Oligonucleotide, antibody and peptide therapeutics  
– from design to the clinic**

Edited by John Goodchild & Patrick L Iversen

Will contain:

**Caroline Créput, Antoine Durrbach, Benjamin Deroué &  
Bernard Charpentier**

New therapeutic targets for antibodies and recombinant proteins in organ transplantation

**Yoshitaka Isaka**

DNAzymes as potential therapeutic molecules

**Marcella Faria & Henning Ulrich**

Sugar boost when modification of ribose improves oligonucleotide performance

**Kuang-Yuh Chyu, Jan Nilsson & Prediman K Shah**

Active and passive immunization for atherosclerosis

**Christopher D Kontos & Brian H Annex**

Engineered transcription factors for therapeutic angiogenesis

**Nanda D Sinha & Dennis P Michaud**

Recent developments in chemistry, analysis and control for manufacture of therapeutic grade synthetic oligonucleotides

**Andrew S Peek & Mark A Behlke**

Site selection and design of siRNAs

**Glenda E Gray, Caroline T Tiemessen & Guy de Bruyn**

Immune-based prevention of mother-to-child HIV-1 transmission

**Vira Bitko & Sailen Barik**

Intranasal antisense therapy: Preclinical models with a clinical future?

**Ted Chu, Jessica Ebright & Andrew D Ellington**

Using aptamers to identify and enter cells

**Wenyi Gu, Lisa N Putral, Aaron Irving & Nigel AJ McMillan**

The development and future of oligo-based therapies for cervical cancer